Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | OGA | O60502 | 7/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | LCAT | P04180 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147067 | 0.87 | OPRM1 (0.43) | OGAPANK3LCATACACB | |
| SCHEMBL23107193 | 0.84 | PANK3 (0.42) | OGAPANK3LCATACACB | |
| SCHEMBL15247287 | 0.84 | PANK3 (0.41) | OGAPANK3LCATACACB | |
| SCHEMBL15247290 | 0.83 | LCAT (0.44) | OGAPANK3LCATACACB | |
| SCHEMBL14349207 | 0.80 | PANK3 (0.46) | OGAPANK3ACACB | |
| SCHEMBL13466366 | 0.80 | CNR2 (0.48) | OGAPANK3ACACB | |
| SCHEMBL26846118 | 0.80 | OGA (0.39) | OGAPANK3CCR6ACACB | |
| SCHEMBL26702776 | 0.79 | OGA (0.42) | OGAPANK3LCATACACB | |
| SCHEMBL4547927 | 0.79 | CNR2 (0.50) | OGAPANK3 | |
| SCHEMBL17693895 | 0.79 | CACNA1H (0.41) | PANK3LCATACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK1G3 | PDE10A 1123/4885OGA 4270/4885PANK3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.